{"ATC Code":"N05CF02","Abbreviation":"","Aliases":["Zolpidemum","Sanval","Zolpidem civ","N,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide","N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide","SL800750","SL 800750","SL 80-0750","N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide","N,n,6-trimethyl-2-p-tolyl-imidazo(1,2-a)pyridine-3-acetamide"],"Biological Half-Life":"The average zolpidem elimination half-life was 2.6 and 2.5 hours, for the 5 and 10 mg tablets, respectively.","CAS":"82626-48-0","ChEBI":"CHEBI:10125","ChEMBL":"CHEMBL911","ChemicalClasses":["imidazopyridine"],"Chirality":"achiral","Classes":null,"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives","Drug Indication":"This drug is indicated for the short-term treatment of insomnia in adults characterized by difficulties with sleep initiation.","DrugClasses":["depressant"],"DurationOfAction":"3 hours\u003ca href='#cite_note-5'\u003e\u003csup\u003e[5]\u003c/sup\u003e\u003c/a\u003e \u003ca href='#cite_note-6'\u003e\u003csup\u003e[6]\u003c/sup\u003e\u003c/a\u003e","EliminationHalfLife":"2 – 3 hours\u003ca href='#cite_note-4'\u003e\u003csup\u003e[4]\u003c/sup\u003e\u003c/a\u003e","Erowid Experience Reports":[{"Author":"sim","Id":"100421","Title":"I Still Feel Normal"},{"Author":"65daysofstatic","Id":"104679","Title":"Everything Was Great"},{"Author":"pl8","Id":"105971","Title":"No Effects"},{"Author":"Stable_Sauce","Id":"106840","Title":"Peaceful Trip"},{"Author":"frauverrueckt","Id":"107653","Title":"Two Continents and Explosive Orgasm"},{"Author":"Aither","Id":"108340","Title":"Gradually Increasing Dosage Felt Great"},{"Author":"Dr. Antithesis","Id":"109873","Title":"My Love My Enemy My Vice"},{"Author":"goddess09","Id":"110065","Title":"Making Embarrassing Posts"},{"Author":"joey","Id":"110344","Title":"I Can't Even Explain"},{"Author":"Bill","Id":"110950","Title":"So Not the Drug for Me"},{"Author":"cantsleep","Id":"111233","Title":"Worked as Intended the First Time"},{"Author":"Saturdaze","Id":"112082","Title":"Foggy Fun"},{"Author":"HaldolHunter","Id":"114127","Title":"Drifting Into Oblivion"},{"Author":"Red Moon","Id":"114798","Title":"In the Pursuit of Sleep"},{"Author":"Agent zoom","Id":"114698","Title":"A Journey Into Chaos"},{"Author":"onychophagist","Id":"115155","Title":"As It Is Supposed to Work"},{"Author":"US Air Force Airman","Id":"115867","Title":"Kept Me Wide Awake"},{"Author":"D X Meth-Head","Id":"116020","Title":"Plum Women, Pupa and Pine Nuts"},{"Author":"Adrenochrome","Id":"12427","Title":"Totally Disconnected From My Mind"},{"Author":"benzo","Id":"14039","Title":"Psychedelic Sleeping Pill?"},{"Author":"Weather","Id":"14182","Title":"Overall Pretty Impressive"},{"Author":"Rhiannon","Id":"13164","Title":"Trips And Falls"},{"Author":"A Random kat","Id":"14413","Title":"Confusion and Extreme Memory Loss"},{"Author":"pillhead987","Id":"15869","Title":"I Felt Like I Wasn't in My Body"},{"Author":"PsYkE","Id":"17557","Title":"Strange and Erratic"},{"Author":"Dr. Homolka","Id":"21774","Title":"Not Fun at All"}],"European Community (EC) Number":"617-367-3","FDA Pharmacological Classification":"7K383OQI23","FullSalts":["Zolpidem hydrobromide","Zolpidem hydrochloride","Zolpidem tartrate"],"HMDB ID":"HMDB0005023","HeavyAtomCount":23,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives","IUPACName":"N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide","InChI":"InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3","InChIKey":"ZAFYATHCZYHLPB-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Endogenous compounds and drugs that bind to and activate GABA-A RECEPTORS. (See all compounds classified as GABA-A Receptor Agonists.)","Melting Point":"193-197","MolecularFormula":"C\u003csub\u003e19\u003c/sub\u003eH\u003csub\u003e21\u003c/sub\u003eN\u003csub\u003e3\u003c/sub\u003eO","MolecularWeight":"307.4 g/mol","Pharmacodynamics":"**Effects on the central nervous system (CNS)**  This drug has CNS depressant effects, which may include somnolence, decreased alertness, sedation, drowsiness, dizziness,  and other changes in psychomotor function.  Due to the above effects, the FDA has recommended an initial dose of zolpidem (immediate-acting) is a single dose of 5 mg for women and a single dose of 5 or 10 mg for men, immediately before bedtime with at least 7-8 hours remaining before the planned time of awakening. Refer to product labeling for detailed information,.   **Effects on memory**  Controlled studies in adults using objective measures of memory demonstrated no significant evidence of next-day memory impairment after the administration of zolpidem. On the contrary, in a clinical study involving the administration of zolpidem doses of 10 and 20 mg, a  marked reduction in a next-morning recall of information relayed to subjects during peak drug effect (90 minutes after dosing) was observed. These subjects experienced a condition known as _anterograde amnesia_. Subjective evidence from adverse event data has suggested that anterograde amnesia may occur after zolpidem administration, mainly at doses above 10 mg.  **Effects on psychomotor function**  This drug may cause decreased psychomotor performance. Additive psychomotor effects may occur with other drugs that cause depression of psychomotor function, including alcohol. Patients taking zolpidem should be cautioned against participating in hazardous activities or occupations requiring complete mental alertness or motor coordination, including operating machinery or driving a motor vehicle after ingesting the drug. Potential impairment of the performance of the above types of activities may also occur the day after zolpidem ingestion, especially at higher doses and ingestion of the extended-release form,.   **Effects on insomnia and sleep stages**  Evidence suggests that this drug is associated with minimal rebound insomnia. During clinical trials with patients using zolpidem on an ‘as-needed’ basis, zolpidem use resulted in global improvements in sleep. Zolpidem has been demonstrated to decrease sleep latency (the time it takes to fall asleep) for up to 35 days in controlled clinical studies. In studies measuring the percentage of sleep time spent in each sleep stage, zolpidem has primarily been shown to preserve sleep stages. Sleep time spent in stages 3 and 4 (deep sleep) was measured as similar to placebo with only minor and inconsistent changes in REM (paradoxical) sleep at the recommended dose.  **Next-day residual effects**   In 2013, the FDA issued a statement warning that patients who take zolpidem extended-release (Ambien CR)―either 6.25 mg or 12.5 mg―should not drive or participate in other activities requiring full mental alertness the day after taking the drug, due to the fact that zolpidem concentrations can remain increased the next day, and impair the ability to perform these activities,.  Patients may decrease their risk of next-morning impairment by taking the lowest dose of their insomnia medicine that treats their symptoms, according to the FDA. Specific dosing recommendations for both men and women are included in this statement. This information is also available on product labeling,.   **Rebound effects**   There was no polysomnographic (objective) evidence of rebound insomnia at normal doses,  in studies evaluating sleep on the nights following discontinuation of zolpidem tartrate. Subjective evidence of impaired sleep in the elderly on the first post-treatment night was observed at doses higher than the recommended 5mg dose for elderly patients.","Physical Description":"Solid","PrevSalts":["hydrobromide","hydrochloride","tartrate"],"PubChemId":5732,"Record Description":["Zolpidem is an imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position. It has a role as a central nervous system depressant, a GABA agonist and a sedative.","Zolpidem is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance.","Zolpidem, also known as Ambien, is a hypnotic drug that was initially approved by the FDA in 1992.  Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of sleep, and decreases the number of awakenings during sleep in patients with temporary (transient) insomnia.  It is available in both immediate acting and extended release forms,.   Its tolerability profile is favorable when administered according to the manufacturer’s instructions, with a low risk of drug withdrawal, drug dependence, and drug tolerance. In addition, zolpidem improves sleep quality in patients suffering from chronic insomnia and can show mild muscle relaxant properties. Research also shows that zolpidem is rapid and effective in restoring brain function for patients in a vegetative state following brain injury. This drug has the propensity to completely or partially reverse the abnormal metabolism of damaged brain cells after injury,.","Zolpidem is a gamma-Aminobutyric Acid A Receptor Positive Modulator. The mechanism of action of zolpidem is as a GABA A Receptor Positive Modulator. The physiologic effect of zolpidem is by means of Central Nervous System Depression.","Zolpidem is a gamma-Aminobutyric Acid-ergic Agonist. The mechanism of action of zolpidem is as a GABA A Agonist. The physiologic effect of zolpidem is by means of Central Nervous System Depression. The chemical classification of zolpidem is Pyridines.","Zolpidem is a benzodiazepine receptor agonist that is used for the treatment of insomnia. Zolpidem has rarely been implicated in causing serum enzyme elevations and has not been reported to cause clinically apparent liver injury.","ZOLPIDEM is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and is indicated for insomnia and has 16 investigational indications. This drug has a black box warning from the FDA.","An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.","See also: Zolpidem Tartrate (has salt form).","Zolpidem is an imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position. It has a role as a central nervous system depressant, a GABA agonist and a sedative.","LiverTox|CNS|Sedative/Hypnotic|Benzodiazepine receptor blocker"],"RefCount":7,"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Zolpidem","Name":"Zolpidem","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q218842","Name":"Zolpidem","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00425","Name":"Zolpidem","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/5732","Name":"Zolpidem","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL911","Name":"Zolpidem","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:10125","Name":"Zolpidem","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=82626-48-0","Name":"Zolpidem","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0005023","Name":"Zolpidem","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07219","Name":"Zolpidem","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/7K383OQI23","Name":"Zolpidem","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID7045946","Name":"Zolpidem","Sub":false}]}],"Refs":["National Center for Biotechnology Information. PubChem Compound Summary for CID 5732, Zolpidem. Accessed June 27, 2025. \u003ca href=https://pubchem.ncbi.nlm.nih.gov/compound/5732\u003ehttps://pubchem.ncbi.nlm.nih.gov/compound/5732\u003c/a\u003e","U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Zolpidem. UNII: 7K383OQI23. Global Substance Registration System. Accessed June 27, 2025. \u003ca href=https://gsrs.ncats.nih.gov/ginas/app/beta/substances/7K383OQI23\u003ehttps://gsrs.ncats.nih.gov/ginas/app/beta/substances/7K383OQI23\u003c/a\u003e","Scheduling of zolpidem (Stilnox). February 21, 2008. Accessed June 27, 2025. \u003ca href=https://www.tga.gov.au/scheduling-zolpidem-stilnox\u003ehttps://www.tga.gov.au/scheduling-zolpidem-stilnox\u003c/a\u003e","Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clinical Pharmacokinetics. September 1, 1995; 29(3):142–153.","Sabe M, Kashef H, Gironi C, Sentissi O. Zolpidem stimulant effect: Induced mania case report and systematic review of cases. Progress in Neuro-Psychopharmacology \u0026 Biological Psychiatry. August 1, 2019; 94:109643.","AMBIEN- zolpidem tartrate tablet, film coated. August 19, 2024. Accessed June 27, 2025. \u003ca href=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c36cadf4-65a4-4466-b409-c82020b42452\u003ehttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c36cadf4-65a4-4466-b409-c82020b42452\u003c/a\u003e"],"SMILES":"CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C","Salts":["hydrobromide","hydrochloride","tartrate"],"SaltsAcidCount":[1,1,1],"SaltsAmineCount":[1,1,2],"SaltsUNII":["MW5XV2E6AB","5XT3YJT4W8","WY6W63843K"],"Scheduling":[{"gov":"Australia","ref":["3"],"schedule":"S4 substance"},{"gov":"Brazil","ref":[],"schedule":"B1 substance"},{"gov":"Canada","ref":[],"schedule":"Schedule IV substance"},{"gov":"Germany","ref":[],"schedule":"prescription only/Anlage III substance"},{"gov":"United Kingdom","ref":[],"schedule":"Class C substance"},{"act":"Controlled Substances Act (CSA)","gov":"United States","ref":[],"schedule":"Schedule I"},{"gov":"United Nations","ref":[],"schedule":"Schedule IV substance"}],"StoreUNII":["7K383OQI23"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="81.279mm" version="1.2" viewBox="0 0 126.008 81.279" width="126.008mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="82.0" stroke="none" width="127.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="125.098" x2="109.858" y1="16.263" y2="16.263"/>
                  
            <g class="bond" id="mol1bnd2">
                        
                <line x1="102.231" x2="109.858" y1="29.468" y2="16.263"/>
                        
                <line x1="100.823" x2="107.042" y1="27.03" y2="16.263"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd3" x1="102.231" x2="86.983" y1="29.468" y2="29.475"/>
                  
            <g class="bond" id="mol1bnd4">
                        
                <line x1="79.361" x2="86.983" y1="16.278" y2="29.475"/>
                        
                <line x1="82.177" x2="88.39" y1="16.278" y2="27.036"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd5" x1="79.361" x2="86.987" y1="16.278" y2="3.074"/>
                  
            <g class="bond" id="mol1bnd6">
                        
                <line x1="102.236" x2="86.987" y1="3.066" y2="3.074"/>
                        
                <line x1="100.828" x2="88.395" y1="5.506" y2="5.512"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd7" x1="109.858" x2="102.236" y1="16.263" y2="3.066"/>
                  
            <line class="bond" id="mol1bnd8" x1="79.361" x2="64.121" y1="16.278" y2="16.278"/>
                  
            <g class="bond" id="mol1bnd9">
                        
                <line x1="55.18" x2="64.121" y1="28.572" y2="16.278"/>
                        
                <line x1="54.246" x2="61.106" y1="25.71" y2="16.278"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd10" x1="55.18" x2="43.925" y1="28.572" y2="24.951"/>
                  
            <line class="bond" id="mol1bnd11" x1="37.498" x2="27.443" y1="25.717" y2="31.518"/>
                  
            <g class="bond" id="mol1bnd12">
                        
                <line x1="14.235" x2="27.443" y1="23.898" y2="31.518"/>
                        
                <line x1="16.674" x2="27.443" y1="22.49" y2="28.703"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd13" x1="14.235" x2="14.235" y1="23.898" y2="8.658"/>
                  
            <g class="bond" id="mol1bnd14">
                        
                <line x1="27.443" x2="14.235" y1="1.038" y2="8.658"/>
                        
                <line x1="27.443" x2="16.674" y1="3.853" y2="10.066"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd15" x1="27.443" x2="40.651" y1="1.038" y2="8.658"/>
                  
            <line class="bond" id="mol1bnd16" x1="40.651" x2="40.651" y1="20.048" y2="8.658"/>
                  
            <g class="bond" id="mol1bnd17">
                        
                <line x1="51.906" x2="40.651" y1="5.038" y2="8.658"/>
                        
                <line x1="52.653" x2="43.09" y1="7.359" y2="10.435"/>
                      
                <line class="hi" stroke="#3050F8" x1="51.906" x2="46.2785" y1="5.038" y2="6.848"/>
                <line class="hi" stroke="#3050F8" x1="52.653" x2="47.8715" y1="7.359" y2="8.897"/>
            </g>
                  
            <line class="bond" id="mol1bnd18" x1="64.121" x2="57.785" y1="16.278" y2="7.567"/>
                  
            <line class="bond" id="mol1bnd19" x1="14.235" x2="1.038" y1="23.898" y2="31.52"/>
                  
            <line class="bond" id="mol1bnd20" x1="55.18" x2="59.907" y1="28.572" y2="43.06"/>
                  
            <line class="bond" id="mol1bnd21" x1="59.907" x2="49.724" y1="43.06" y2="54.398"/>
                  
            <g class="bond" id="mol1bnd22">
                        
                <line x1="50.16" x2="38.19" y1="55.736" y2="53.207"/>
                        
                <line x1="50.664" x2="38.694" y1="53.351" y2="50.822"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="38.19" x2="44.175" y1="53.207" y2="54.4715"/>
                <line class="hi" stroke="#FF0D0D" x1="38.694" x2="44.679" y1="50.822" y2="52.0865"/>
            </g>
                  
            <line class="bond" id="mol1bnd23" x1="49.724" x2="53.217" y1="54.398" y2="65.106"/>
                  
            <line class="bond" id="mol1bnd24" x1="51.574" x2="44.267" y1="72.089" y2="80.224"/>
                  
            <line class="bond" id="mol1bnd25" x1="57.761" x2="69.362" y1="69.586" y2="72.037"/>
                  
            <path class="atom" d="M42.592 26.348h-.72l-2.62 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.769h.578v4.9z" id="mol1atm10" stroke="none"/>
                  
            <path class="atom" d="M57.121 6.434h-.721l-2.619 -4.066h-.03q.012 .238 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" id="mol1atm16" stroke="none"/>
                  
            <path class="atom" d="M37.072 51.245q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM33.208 51.245q.0 .923 .387 1.458q.393 .53 1.221 .53q.839 .0 1.22 -.53q.387 -.535 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.834 .0 -1.227 .524q-.393 .524 -.393 1.453z" fill="#FF0D0D" id="mol1atm20" stroke="none"/>
                  
            <path class="atom" d="M56.392 71.336h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .358 .024 .733v2.738h-.566v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" id="mol1atm21" stroke="none"/>
                
            <line class="hi" id="mol1bnd10" stroke="#3050F8" x1="43.925" x2="49.552499999999995" y1="24.951" y2="26.761499999999998"/>
            <line class="hi" id="mol1bnd11" stroke="#3050F8" x1="37.498" x2="32.4705" y1="25.717" y2="28.6175"/>
            <line class="hi" id="mol1bnd16" stroke="#3050F8" x1="40.651" x2="40.651" y1="20.048" y2="14.352999999999998"/>
            <line class="hi" id="mol1bnd18" stroke="#3050F8" x1="57.785" x2="60.952999999999996" y1="7.567" y2="11.9225"/>
            <line class="hi" id="mol1bnd23" stroke="#3050F8" x1="53.217" x2="51.4705" y1="65.106" y2="59.751999999999995"/>
            <line class="hi" id="mol1bnd24" stroke="#3050F8" x1="51.574" x2="47.920500000000004" y1="72.089" y2="76.1565"/>
            <line class="hi" id="mol1bnd25" stroke="#3050F8" x1="57.761" x2="63.561499999999995" y1="69.586" y2="70.8115"/>
        </g>
          
    </g>
    
</svg>
","Subjective Effects":null,"Title":"Zolpidem","UNII":"7K383OQI23","Wikidata":"Q218842","Wikipedia":"Zolpidem","XLogP":2.5}